Colforsin daropate hydrochloride (CDH) stimulates adenylate cyclase resulting in increase of intracellular cyclic adenosine monophosphate (cAMP), and exhibits positive inotropic, vasodilative, and diuretic effects. In adult, CDH ameliorates the condition of cardiac failure, even when catecholamines do not. We present here CDH worked effectively for a pediatric patient with severe cardiac failure, for whom neither catecholamine nor phosphodiesterase III inhibitor worked. An 11-month-old girl was admitted to our unit because of cardiac failure. She had been diagnosed as congenital mitral regurgitation and multiple anomalies. She had an upper respiratory tract infection, and cardiac failure developed. Her trachea was intubated and mechanical ventilation was started. Dopamine (7μg·kg
-1·min
-1), milrinone (0.5μg·kg
-1·min
-1) administration failed to improve hemodynamics. CVP was 22 mmHg, and echocardiography revealed LVEDd of 34.1 mm. Serum brain natriuretic peptide (BNP) level was 13,987 pg·ml
-1. Because of cardiogenic pulmonary edema, oxygenation was poor (P/F ratio 89 mmHg). While CDH was rarely reported for pediatric patients, we started CDH (0.1∼0.16μg·kg
-1·min
-1) resulting in increase of urinary output. Two weeks after CDH administration, general edema disappeared and she lost 1.5 kg of weight. CVP decreased to 7 mmHg, BNP decreased to 351 pg·ml
-1, and P/F ratio increased above 400 mmHg. She was weaned from a ventilator successfully. CDH was administered for 2 months. CDH was useful for pediatric patients with refractory cardiac failure.
View full abstract